no desc

Effectiveness and Tolerability of Trimetazidine 80 Mg Once Daily in Patients with Stable Angina Uncontrolled with Bisoprolol-Based Therapy: The Modus Vivendi Observational Study

At the end of 2021, a study to evaluate the effect of adding trimetazidine 80 mg once daily (TMZ 80 OD) to treat patients with persistent symptoms despite treatment with background antianginal therapies including maximally tolerated bisoprolol was published. The Modus Vivendi study, led by Yuri Lopatin, was conducted between October 2017 and July 2018 in Russia.

  • The main results of this study, regardless the doses of Bisoprolol, were:

  • The number of angina attacks was reduced in -74% at month 3 vs baseline

  • The mean short-acting nitrates consumption decreased in -78% at month 3 vs baseline

  • After 3 months, 44.0% participants reported no problems on all five dimensions of the EQ-5D-3L* vs 2.6% at baseline, meaning improvement in quality of life

  • Significant improvement in treatment adherence was observed

The results achieved in this study supports that the addition of Trimetazidine OD 80 to the treatment, including the ones with maximally tolerated bisoprolol, reduces angina attacks and improves quality of life, regardless of the background treatment.

If you want to learn more about this topic, please find the : entire study here.

EQ-5D-3L: EuroQoL 5-dimension 3-level questionnaire
SCAC 04/22 DM 132 SERVIER – For the exclusive use of healthcare professionals
Background Vimeo Live Event

Keep up to date with our content

Subscribe to our newsletter so that you are always up to date with the news.

You can unsubscribe at any time by clicking on the link in our emails.
SERVIER CENTRAL AMERICA AND THE CARIBBEAN, S.A.Edificio Dream Plaza, Costa Del Este, Ciudad de Panamá, Panamá+507-301-0227Todo el contenido de este sitio web, es sólo para los profesionales de la salud y un uso interno del evento.
LogoCopyright © 2022 Servier University by SERVIER CENTRO AMÉRICA Y EL CARIBE, S.A.